Literature DB >> 29193842

Determining the Risk Factors and Clinical Features Associated With Severe Gastrointestinal Dysmotility in Systemic Sclerosis.

Zsuzsanna H McMahan1, Julie J Paik1, Fredrick M Wigley1, Laura K Hummers1.   

Abstract

OBJECTIVE: A subset of patients with systemic sclerosis (SSc) develop severe gastrointestinal (GI) dysmotility. We sought to determine predictors of severe SSc GI dysmotility and to identify distinct features associated with this phenotype.
METHODS: Patients with SSc who required supplemental nutrition (enteral or parenteral tube feeding) were compared to SSc patients with mild GI symptoms in a cross-sectional analysis. The association between severe GI dysmotility and clinical and serologic features was examined using logistic regression. Baseline data were examined to determine predictors of developing severe GI dysfunction using Cox regression.
RESULTS: SSc patients with severe GI dysmotility (n = 66) were more likely than those patients with mild GI symptoms (n = 1,736) to be male (odds ratio [OR] 2.47 [95% confidence interval (95% CI) 1.34-4.56]; P = 0.004), and to have myopathy (OR 5.53 [95% CI 2.82-10.82]; P < 0.001), and sicca symptoms (OR 2.40 [95% CI 1.30-4.42]; P = 0.005), even after adjustment for potential confounders. Baseline features that were associated with the future development of severe GI dysfunction included male sex (hazard ratio [HR] 2.99 [95% CI 1.53-5.84]; P = 0.001) and myopathy (HR 5.08 [95% CI 2.21-11.67]; P < 0.001).
CONCLUSION: Distinct clinical features are present in SSc patients who are at risk of developing severe GI dysmotility. This finding is not only important clinically but also suggests that a unique pathologic process is at work in these patients.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2018        PMID: 29193842     DOI: 10.1002/acr.23479

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  10 in total

1.  Evaluation of risk factors for pseudo-obstruction in systemic sclerosis.

Authors:  Eric Dein; Pei-Lun Kuo; Yun Soo Hong; Laura K Hummers; Christopher A Mecoli; Zsuzsanna H McMahan
Journal:  Semin Arthritis Rheum       Date:  2019-05-23       Impact factor: 5.532

2.  Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches.

Authors:  Anna-Maria Hoffmann-Vold; Elizabeth R Volkmann
Journal:  J Scleroderma Relat Disord       Date:  2019-12-20

Review 3.  Management of scleroderma gastrointestinal disease: Lights and shadows.

Authors:  Jenice X Cheah; Dinesh Khanna; Zsuzsanna H McMahan
Journal:  J Scleroderma Relat Disord       Date:  2022-04-19

4.  Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed by the COMPASS-31 Questionnaire.

Authors:  Brittany L Adler; James W Russell; Laura K Hummers; Zsuzsanna H McMahan
Journal:  J Rheumatol       Date:  2018-06-15       Impact factor: 4.666

5.  Anti-RNPC-3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate-to-Severe Gastrointestinal Dysmotility.

Authors:  Zsuzsanna H McMahan; Robyn T Domsic; Lei Zhu; Thomas A Medsger; Livia Casciola-Rosen; Ami A Shah
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-08-06       Impact factor: 4.794

6.  Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.

Authors:  Zsuzsanna H McMahan; Ana E Tucker; Jamie Perin; Elizabeth R Volkmann; Subhash Kulkarni; Harvey A Ziessman; Pankaj J Pasricha; Fredrick M Wigley
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-01-25       Impact factor: 4.794

7.  Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes.

Authors:  Alain Lescoat; Susan L Murphy; David Roofeh; John D Pauling; Michael Hughes; Robert Sandler; François Zimmermann; Rachel Wessel; Whitney Townsend; Lorinda Chung; Christopher P Denton; Peter A Merkel; Virginia Steen; Yannick Allanore; Francesco Del Galdo; Dominique Godard; David Cella; Sue Farrington; Maya H Buch; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2020-10-05

8.  High risk of gastrointestinal hemorrhage in patients with systemic sclerosis.

Authors:  Yi-Ting Lin; Yun-Shiuan Chuang; Jiunn-Wei Wang; Ping-Hsun Wu
Journal:  Arthritis Res Ther       Date:  2019-12-26       Impact factor: 5.156

9.  Slow Colonic Transit in Systemic Sclerosis: An Objective Assessment of Risk Factors and Clinical Phenotype.

Authors:  Jenice X Cheah; Jamie Perin; Elizabeth R Volkmann; Laura K Hummers; Pankaj J Pasricha; Fredrick M Wigley; Zsuzsanna H McMahan
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-08-09       Impact factor: 5.178

10.  Comparing Clinical, Imaging, and Physiological Correlates of Intestinal Pseudo-Obstruction: Systemic Sclerosis vs Amyloidosis and Paraneoplastic Syndrome.

Authors:  Rahul Pamarthy; Antonio Berumen; Margaret Breen-Lyles; Madhusudan Grover; Ashima Makol
Journal:  Clin Transl Gastroenterol       Date:  2020-08       Impact factor: 4.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.